Phase 2 randomized, open-label, multiple dose clinical trial of bitopertin in patients with Erythropoietic Protoporphyria or X-linked Protoporphyria
Latest Information Update: 14 May 2025
At a glance
- Drugs Bitopertin (Primary)
- Indications Erythropoietic protoporphyria
- Focus Therapeutic Use
- Acronyms BEACON
Most Recent Events
- 21 Jan 2025 According to a Disc Medicine Media Release, company planning to submit NDA under accelerated approval pathway in H2 2025 based on existing clinical data, including results from BEACON and AURORA Phase 2 trials.Scheduled pre-NDA meeting to align with the FDA on format and content of the NDA package.
- 09 Dec 2024 According to a Disc Medicine Media Release, data from the study were presented at the ASH 2024 annual meeting in San Diego, CA.
- 09 Dec 2024 Results presented in the Disc Medicine Media Release.